BiologIC Technologies has been awarded a Biomedical Catalyst grant of £435,000 from Innovate UK, as part of a UK-based consortium, to develop an Advanced Fluidic Control System for continuous bioprocessing. BiologIC will deploy its full stack industry 4.0 technology platform to develop a smart fluidic system with integrated inline sensing. The system will enable the control of continuous flow between unit operations in the manufacture of biologics such as monoclonal antibodies, vaccines or other therapies.
The consortium comprises BiologIC Technologies, Biopharm Services, CPI, Pall Corporation, and SCIEX.
The accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing but has emphasized the need to find ways to quickly and reliably develop and manufacture life changing drugs and therapies at scale. This project aims to address some of the manufacturing challenges faced in the pharmaceutical industry by increasing flexibility and sustainability, reducing batch failures and paving the way towards real-time product release of biopharmaceutical drugs.
Richard Vellacott, CEO of BiologIC Technologies said: “As pioneers in next generation bioprocessing, we are delighted to collaborate with world class partners to significantly intensify the continuous manufacturing of therapies and make them more accessible to the patients that need them.”